The US dollar was slightly higher on Friday, coming off its strongest level for the day, as risk appetite returned to the market in the afternoon with US equities recovering from early losses and Treasury yields extending their rise.
Investors also consolidated gains made on other currencies at the expense of the US dollar ahead of a long weekend in the US.
Financial markets are closed tomorrow for Presidents Day.
The outlook for the US dollar remained lower, according to Marshall Gittler, head of investment research at BDSwiss Group.
The greenback is “considered the safest of safe havens and tends to fall when people are not looking for safe havens,” Gittler said. “With markets rallying and the US Fed on hold indefinitely, I expect the dollar to be widely used as a funding currency, pushing its value down.”
In afternoon trading, the dollar index rose 0.1 percent to 90.494 after subdued volumes in Asia because of the Lunar New Year.
On the week, the index fell 0.6 percent, its first losing week in three — in what ING Groep NV analysts described as a “consolidative mood” amid uncertainty about the pace of the US economic recovery. Weaker-than-expected weekly US jobless claims data on Thursday added to concerns the US dollar’s previous rally had priced in too fast an economic rebound.
The US dollar was up 0.2 percent against the yen at ￥104.97. It fell 0.4 percent on the week, its steepest fall since mid-December.
The euro slipped 0.1 percent to US$1.2116, but on the week, the single European currency rose 0.5 percent. The British pound rose 0.2 percent versus the US dollar to US$1.3848, despite data showing Britain’s economy suffered a record slump last year, although it did grow in the final quarter.
The Australian dollar, a proxy for risk appetite, rallied from lows to trade flat on the day at US$0.7753. The New Zealand dollar likewise cut its losses against the greenback.
UNCONVINCING: The US Congress questioned whether the company’s Chinese owners pose a national security risk and how the app might influence young users TikTok chief executive officer Shou Chew (周受資), confronted with an unforgiving, distrustful US Congress, tried to give answers in his testimony on Thursday that avoided offending either the US government or China. However, his evasiveness left Congress unsatisfied, with representatives hungrier than ever to punish TikTok for ties to its parent company ByteDance Ltd (字節跳動), based in Beijing. He did not bring his company any closer to a resolution. Politically, TikTok is in a tougher spot. Its executives had been discussing divesting from ByteDance to resolve US national security concerns, people familiar with the matter told Bloomberg. However, China this week said
The Investment Commission yesterday approved a Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) application to invest an additional US$3.5 billion in its Arizona subsidiary to manufactured advanced chips. The world’s largest contract chipmaker’s board of directors last month approved the funding project after TSMC started moving manufacturing equipment into the fab in December last year in preparation for the production of 4-nanometer chips next year. TSMC said it has also commenced the second phase of facility construction in Arizona. The second fab is to produce semiconductors using 3-nanometer technology in 2026. Altogether, TSMC plans to spend US$40 billion on the Arizona fabs, doubling its
Microsoft Corp has threatened to cut off access to its Internet search data, which it licenses to rival search engines, if they do not stop using it as the basis for their own artificial intelligence (AI) chat products, people familiar with the dispute have said. The software maker licenses the data in its Bing search index — a map of the Internet that can be quickly scanned in real time — to other companies that offer Web search, such as Apollo Global Management Inc’s Yahoo and DuckDuckGo. Last month, Microsoft integrated a cousin of ChatGPT, OpenAI’s AI-powered chat technology, into Bing. Rivals
Sanofi SA’s drug Dupixent succeeded in a late-stage trial for chronic obstructive pulmonary disease (COPD), raising the odds that the blockbuster would be the first biologic medicine cleared to treat the lung disorder. Dupixent, which is already prescribed for asthma and some skin conditions, showed a 30 percent reduction in the rate at which patients’ COPD worsened compared with those who received a placebo during the stage-three Boreas trial, the company said in a statement yesterday. The positive data could herald a new era of cutting-edge treatments for the life-threatening respiratory affliction and provide another major boost in demand for the French
RSS